Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Johnson & Johnson (JNJ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and Johnson & Johnson (JNJ – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen (AMGN)
Goldman Sachs analyst Salveen Richter maintained a Buy rating on Amgen yesterday and set a price target of $415.00. The company’s shares closed last Wednesday at $366.20.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $361.94, implying a 2.8% upside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $406.00 price target.
See the top stocks recommended by analysts >>
Johnson & Johnson (JNJ)
In a report released yesterday, Asad Haider from Goldman Sachs maintained a Buy rating on Johnson & Johnson, with a price target of $250.00. The company’s shares closed last Wednesday at $234.47.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $243.00 average price target, which is a 3.4% upside from current levels. In a report issued on January 28, Morgan Stanley also upgraded the stock to Buy with a $262.00 price target.
